… (HER2)-mutated metastatic breast cancer (mBC). The data … for Medical Oncology Breast Cancer 2025 Annual Meeting … Genentech, Roche), lapatinib (24%; Tykerb; Novartis), trastuzumab deruxtecan (9% … HER2-mutated metastatic breast cancer, particularly those who …

… resistant advanced HER2-postive breast cancer,” lead study author … , incurable HER2-positive breast cancer, irrespective of PD- … 4%; 17%) and lapatinib (Tykerb; 20%; 12%; 6%). Most … breast cancer: BCT1703 DIAmOND. Presented at: 2025 ESMO Breast Cancer Congress …

… patients with HER2-positive metastatic breast cancer who had previously received HER2 … advanced or metastatic HER2-expressing breast cancer with an ECOG performance status … ; 73%), pertuzumab (87%; 67%), lapatinib (Tykerb; 23%; 27%), tucatinib (6%; 13% …

… with HER2-positive metastatic breast cancer and again when it … survival (PFS) vs lapatinib (Tykerb) plus capecitabine and showed … Congress on the Future of Breast Cancer® (IBC) occurring on … ;West...[for] HER2-positive breast cancer in the curative setting, …

… (HER2+) advanced metastatic breast cancer (mBC) with liver … compared with the lapatinib (Tykerb; GSK)-capecitabine regimen. … positive liver metastatic advanced breast cancer. Front Oncol. April … for HER2-positive metastatic breast cancer: a systematic review …

… receptor-positive (HER2+) breast cancer (BC), according to … understand how PAK5 affects breast cancer, researchers measured its … both trastuzumab and lapatinib (Tykerb; GSK), another targeted … accumulation in HER2-positive breast cancer. Cell Death & …

… treatments specifically targeting HER2-positive breast cancer brain metastases,” the authors explained … patients with no prior lapatinib (Tykerb) exposure, and cohort 3B ( … sequencing treatments for patients with breast cancer brain metastases,” the authors …

… T-DM1, lapatinib (Tykerb) plus capecitabine, and … with HER2-positive metastatic breast cancer for brain metastases … HER2+ Breast Cancer. Presented at: 42nd Annual Miami Breast Cancer Conference. … HER2-positive metastatic breast cancer and brain metastases: …

… ) benefit vs lapatinib (Tykerb) plus capecitabine for the … HER2-positive advanced breast cancer who experienced disease … or metastatic breast cancer or locally advanced breast cancer not amenable … HER2-positive advanced breast cancer. Signal Transduct Target …

… and EGFR-positive (EGFR+) breast cancer (BC). The data … cells. The anti-breast cancer effect happens when … tanshinlactone worked against breast cancer cells that resist (Tykerb; Novartis), a … Tanshinlactone triggers methuosis in breast cancer cells via NRF2 …